# Vincent Ling

> Vincent Ling is the Chief Business Officer of Morphocell Technologies, a Laval-based regenerative medicine company building iPSC-derived engineered tissues to treat severe organ dysfunction, starting with liver disease. A biotech and pharma veteran of three decades, he spent 12 years at Takeda's Center for External Innovation, where he identified and backed the Kariko-Weissman mRNA platform out of the University of Pennsylvania - the science that became the first COVID mRNA vaccines and earned the 2023 Nobel Prize. He has held leadership roles at Genetics Institute, Adnexus Therapeutics, and Neurotech Pharmaceuticals, and advises the Gates Foundation and academic institutions.

- **Role:** Chief Business Officer at Morphocell Technologies
- **Organizations:** Morphocell Technologies, Takeda Pharmaceuticals, Neurotech Pharmaceuticals, Adnexus Therapeutics, Genetics Institute (now Wyeth), Dragonfly Sciences, Bill & Melinda Gates Foundation
- **Education:** BA, University of California, Berkeley, MS and PhD, University of Illinois, Postdoctoral research, Harvard University
- **Known for:** Identified and backed the Kariko-Weissman mRNA vaccine technology at Takeda, which became the first COVID mRNA vaccine and earned the 2023 Nobel Prize in Physiology or Medicine, Led early-stage pipeline identification, financing, and development across therapeutic areas and billion-dollar franchises at Takeda over 12 years, Built a three-decade career across cell therapy, biologics, genetic engineering, novel biomaterials, and cellular bio-delivery systems

## Career timeline

- **—** — Earned BA from UC Berkeley, then MS and PhD from the University of Illinois
- **—** — Postdoctoral research at Harvard University
- **—** — Leadership role at Genetics Institute (now Wyeth)
- **—** — Head of Biological Sciences for Encapsulated Cell Therapy at Neurotech Pharmaceuticals
- **—** — Leadership role at Adnexus Therapeutics
- **—** — Vice President at Dragonfly Sciences
- **—** — Joined Takeda Pharmaceuticals; Senior Director at the Center for External Innovation (12 years)
- **—** — Identified and supported the Kariko-Weissman mRNA platform from the University of Pennsylvania, which became the first COVID mRNA vaccine
- **2024-08** — Appointed Chief Business Officer of Morphocell Technologies

## Achievements

- Identified and backed the Kariko-Weissman mRNA vaccine technology at Takeda, which became the first COVID mRNA vaccine and earned the 2023 Nobel Prize in Physiology or Medicine
- Led early-stage pipeline identification, financing, and development across therapeutic areas and billion-dollar franchises at Takeda over 12 years
- Built a three-decade career across cell therapy, biologics, genetic engineering, novel biomaterials, and cellular bio-delivery systems
- Serves as an advisor to the Bill & Melinda Gates Foundation and several academic and non-profit institutions

## Latest updates

- **2024-08** — Appointed Chief Business Officer of Morphocell Technologies.
- **2025-12** — Morphocell raised a Series A reported at $50M, part of roughly $90M total funding, while Ling leads business development.

## Links

- Website: https://morphocell.com
- LinkedIn: http://www.linkedin.com/in/vincentling

---

Profile page: https://yespress.io/vincent-ling
Published by YesPress — https://yespress.io
Last updated: 2026-06-04